Pharmalot -- Kelly Martin is always pissing one big investor or another. Two years ago, one of them accused the Elan ceo of mishandling the marketing of the Tysabri multiple sclerosis treatment and failing to control costs (back story). He survived a protracted spat by closing offices and striking a complicated and controversial deal with Johnson & Johnson.
